Lol indeed my friend. I recall them saying they will submit NDA to FDA in 2022 for Hybryte. With the data provided for the efficacy of Hybryte I think it has a good chance of approval. With the submission of this we should get a bump up in share price and avoid a RS to stay listed on big boards. After this bump up in share price they will need to do a offering to pad their bank account to keep the company going. At this current price we could see a 100 - 150% gain. Best to sell the news and buy back in after offering. This is all my opinion. Good luck!
News 
Market Data 
Discover 
